Reevaluating Heart Treatment: Aspirin vs. Clopidogrel

There’s a growing skepticism about a traditional approach to managing coronary heart disease. Many older patients have been advised to take low-dose aspirin daily to prevent further heart attacks or strokes. However, new evidence suggests there might be a more effective alternative.

A recent meta-analysis conducted by a team of cardiologists indicates that clopidogrel, which inhibits blood platelet clumping, could be a better long-term choice for patients already diagnosed with coronary artery disease.

This oral medication shows effectiveness across a variety of demographics, making it quite versatile in its application. Plus, it excels at ‘thinning’ the blood, which is crucial.

Compared to aspirin, clopidogrel can reduce the risk of future heart attacks, strokes, or cardiovascular-related deaths by around 14 percent—without the added concern of excessive bleeding.

It’s worth noting that clopidogrel has primarily been examined as a secondary treatment, mostly for those who have already experienced a significant cardiac event.

The study’s authors suggest that clopidogrel should be considered the go-to long-term anti-platelet option for patients with established coronary artery issues. The research team was led by Ki Hong Choi from Sungkyunkwan University in South Korea and Marco Valgimigli from the Cardiocentro Ticino Institute in Switzerland.

Clopidogrel, commonly known by its brand name Plavix, is often applied as a short-term remedy post-heart attack or stroke. In fact, it ranked among the top 50 most prescribed medications in the U.S. in 2023.

The American Heart Association (AHA) currently recommends clopidogrel instead of daily aspirin for patients with peripheral artery disease since it’s shown to be more effective in preventing major vascular events.

However, despite some recent trials hinting that clopidogrel also offers benefits for coronary artery disease, it’s still primarily suggested for those who can’t tolerate aspirin.

Some cardiologists argue that this guidance is outdated. They point out that the long-term use of aspirin has been backed by dated studies when modern treatment options weren’t yet available.

The authors of the meta-analysis compiled findings from several randomized trials, evaluating clopidogrel against aspirin, covering nearly 29,000 patients in total. Half of these individuals received clopidogrel, while the other half were on aspirin.

After over five years of observation, those on clopidogrel exhibited fewer significant cardiovascular or cerebrovascular incidents compared to those on aspirin. Interestingly, even people of East Asian descent, who typically show lesser effects from short-term clopidogrel use, fared better with clopidogrel than with aspirin.

The research team highlighted that, according to their findings, clopidogrel consistently demonstrated superior effectiveness without sacrificing safety compared to aspirin.

This perspective isn’t isolated. A 2020 review from cardiologists at prestigious institutions also called for additional studies on this topic. They acknowledged the well-established role of aspirin during early heart attack treatment but expressed concern over the short follow-up periods of older trials, many of which didn’t utilize low-dose aspirin.

Still, these older studies form the backbone of current guidelines. As always, patients should consult healthcare professionals regarding their treatment options before making any modifications.

It may be prudent to reconsider the risks and benefits of taking low-dose aspirin, especially among older adults who may be more susceptible to bleeding complications. Clopidogrel is positioned as a viable alternative.

This study was published in The Lancet.